Artificial Intelligence
Macular Degeneration Treatment Market Size is projected to reach USD 15.16 billion by 2030, growing at a CAGR of 7.06%: Straits Research
New York, United States, June 19, 2023 (GLOBE NEWSWIRE) — The eye’s macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision because it gives the clear main idea required to see objects. It manifests when the capillaries close to the fovea enlarge and leak. The fluid buildup interferes with light reflection, which causes progressive vision loss. Nutritional therapy can aid treatment in the early stages of dry macular degeneration. A healthy diet rich in antioxidants is part of the plan to sustain the macula’s cells.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/macular-degeneration-treatment-market/request-sample
Rising Impact of Retinal Disorder Drivers on the Global Market
The rising prevalence of retinal diseases has increased the demand for macular degeneration treatment. Eye conditions have emerged as potential threats in many developed and developing countries. Globally, the prevalence of the most severe eye conditions is rising, and vision loss is becoming a serious public health concern. Numerous worldwide retinal diseases that impair vision have been identified by the World Health Organization (WHO). Two of these conditions, refractive errors, and age-related macular disorders, are most prevalent in underdeveloped countries. As a result of the rising prevalence of retinal disorders, it is anticipated that the market for treating macular degeneration will expand significantly over the forecast period.
Rapid Aging Population Creates Tremendous Opportunities
According to the UN’s World Aging Report, 703 million individuals were 65 or older in 2019. By 2050, this number is anticipated to double. The population aged 65 and older increased globally from 6% in 1990 to 9% in 2019. Smart contact lenses and intelligent optometry are two examples of cutting-edge and digital healthcare products that may impact the market under consideration. Future developments in digital technology could affect eye care. Future access to gene chips could lead to more accurate AMD and glaucoma diagnosis and treatment. Due to investments made by businesses and accelerated research, the market is anticipated to grow during the forecast period.
Report Scope
| Report Metric | Details |
| Market Size by 2030 | USD 15,167.69 million |
| Market Size in 2021 | USD 8,208.70 million |
| CAGR | 7.06% (2022-2030) |
| Historical Data | 2019-2020 |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Stage of Disease, Route of Administration, Sales Channels |
| Geographies Covered | North America, Europe, Asia-Pacific, LAME and Rest of the World |
| Key Companies Profiled/Vendors | Novartis AG, Pfizer Inc., Panoptica, Bausch Health Companies Inc., Regeneron Pharmaceutical Inc., Aerie Pharmaceutical Inc., REGENXBIO Inc., and Bayer AG |
| Key Market Opportunities | Rapid Aging Population |
| Key Market Drivers | Rising Impact of Retinal Disorders Improving Investments in Research and Development |
Buy Now Full Report @ https://straitsresearch.com/buy-now/macular-degeneration-treatment-market
Regional Analysis
North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period. The United States represents a sizable portion of the market under study due to several factors, including the burden of the aging population and the prevalence of age-related macular degeneration. The US is dedicated to improving overall population eye health through several initiatives. Along with recent product launches and established healthcare infrastructure, it is also anticipated that the presence of the major market players will hasten the market’s expansion in the United States. Novel macular degeneration treatments are expected to fuel market growth in the United States.
Europe is expected to grow at a CAGR of 6.70%, generating USD 3,531.14 million during the forecast period. The aging population, the rising prevalence of macular degeneration, and sizable R&D expenditures are additional factors influencing the expansion of the French market under investigation. In France, there are an increasing number of cutting-edge research studies being carried out. The funding provided by the government, both at the national and EU agency levels, is primarily to blame. Medical costs are covered by the government and the individual in France, which has one of the best healthcare systems. Over the anticipated period, it is anticipated that these campaigns will increase public awareness and spur rapid market growth in France.
The presence of significant market players, the rising elderly population in Japan, and the rising awareness of macular degeneration in Asia-Pacific all point to a substantial expansion of the Japanese market for macular degeneration treatments. Japan is one of the Asian countries that is aging quickly. In June 2019, Sumitomo Dainippon Pharma Co. Ltd. modified its contract with Healios K.K. for joint development initiatives and other cooperative activities in Japan. The modifications concerned the activities of development and commercialization. Joint development activities will generate retinal pigment epithelial cells from iPS cells to treat age-related macular degeneration and other eye diseases. Due to the rising AMD prevalence and research and development efforts in the area, the market for macular degeneration treatments in Japan is anticipated to increase.
Key Highlights
- The global macular degeneration treatment market size was valued at USD 8,208.70 million in 2021. It is expected to reach USD 15,167.69 million by 2030, growing at a CAGR of 7.06% during the forecast period (2022–2030).
- Based on type, the global macular degeneration treatment market is bifurcated into dry and wet age-related macular degeneration. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.98% over the forecast period.
- Based on the stage of disease, the global macular degeneration treatment market is bifurcated into early-stage AMD, intermediate AMD, and late-stage AMD. The late-stage AMD segment owns the highest market share and is expected to grow at a CAGR of 7.03% during the forecast period.
- Based on the route of administration, the global macular degeneration treatment market is bifurcated into the intravenous route and intravitreal route. The intravitreal route segment is the highest contributor to the market and is expected to grow at a CAGR of 7.10% during the forecast period.
- Based on sales channels, the global macular degeneration treatment market is bifurcated into ambulatory surgical centers and hospitals. The hospital segment owns the highest market share and is expected to grow at a CAGR of 7.04% during the forecast period.
- North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period.
Competitors in Macular Degeneration Treatment Market
- Novartis AG
- Pfizer Inc.
- Panoptica
- Bausch Health Companies Inc.
- Regeneron Pharmaceutical Inc.
- Aerie Pharmaceutical Inc.
- REGENXBIO Inc.
- Bayer AG
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/macular-degeneration-treatment-market/request-sample
Segmentation of Macular Degeneration Treatment Market
By Type
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
By Stage of Disease
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
By Route of Administration
- Intravenous Route
- Intravitreal Route
By Sales Channels
- Ambulatory Surgical Centers
- Hospitals
- Other Sales Channels
By Regions
- North America
- Europe
- Asia-Pacific
- The Middle East and Africa
- South America
TABLE OF CONTENT
- Executive Summary
- Research Scope & Segmentation
- Research Objectives
- Market Definition
- Limitations & Assumptions
- Market Scope & Segmentation
- Currency & Pricing Considered
- Market Opportunity Assessment
- Emerging Regions / Countries
- Emerging Companies
- Emerging Applications / End Use
- Investment Landscape
- New Business Models / Revenue Streams
- TAM
- Market Trends
- Drivers
- Market Warning Factors
- Latest Macro Economic Indicators
- Geopolitical Impact
- Human Factors
- Technology Factors
- Market Assessment
- Porters Five Forces Analysis
- Value Chain Analysis
- Sales And Distribution Channel Analysis
- Case Study Analysis
- Patent Analysis
- M & A Agreements & Collabration Analysis
- ESG TRENDS
- Global Macular Degeneration Treatment Market Size Analysis
- Global Macular Degeneration Treatment Market Introduction
- By Type
- Introduction
- Type By Value
- Dry Age-Related Macular Degeneration
- By Value
- Wet Age-Related Macular Degeneration
- By Value
- Introduction
- By Stage Of Disease
- Introduction
- Stage Of Disease By Value
- Early-Stage AMD
- By Value
- Intermediate AMD
- By Value
- Late-Stage AMD
- By Value
- Introduction
- By Route Of Administration
- Introduction
- Route Of Administration By Value
- Intravenous Route
- By Value
- Intravitreal Route
- By Value
- Introduction
- By Sales Channels
- Introduction
- Sales Channels By Value
- Ambulatory Surgical Centers
- By Value
- Hospitals
- By Value
- Other Sales Channels
- By Value
- Introduction
- North America Market Analysis
- Introduction
- By Type
- Introduction
- Type By Value
- Dry Age-Related Macular Degeneration
- By Value
- Wet Age-Related Macular Degeneration
- By Value
- Introduction
- By Stage Of Disease
- Introduction
- Stage Of Disease By Value
- Early-Stage AMD
- By Value
- Intermediate AMD
- By Value
- Late-Stage AMD
- By Value
- Introduction
- By Route Of Administration
- Introduction
- Route Of Administration By Value
- Intravenous Route
- By Value
- Intravitreal Route
- By Value
- Introduction
- By Sales Channels
- Introduction
- Sales Channels By Value
- Ambulatory Surgical Centers
- By Value
- Hospitals
- By Value
- Other Sales Channels
- By Value
- Introduction
- U.S.
- Canada
- Europe Market Analysis
- Introduction
- By Type
- Introduction
- Type By Value
- Dry Age-Related Macular Degeneration
- By Value
- Wet Age-Related Macular Degeneration
- By Value
- Introduction
- By Stage Of Disease
- Introduction
- Stage Of Disease By Value
- Early-Stage AMD
- By Value
- Intermediate AMD
- By Value
- Late-Stage AMD
- By Value
- Introduction
- By Route Of Administration
- Introduction
- Route Of Administration By Value
- Intravenous Route
- By Value
- Intravitreal Route
- By Value
- Introduction
- By Sales Channels
- Introduction
- Sales Channels By Value
- Ambulatory Surgical Centers
- By Value
- Hospitals
- By Value
- Other Sales Channels
- By Value
- Introduction
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Nordic
- Benelux
- Rest Of Europe
- APAC Market Analysis
- Introduction
- By Type
- Introduction
- Type By Value
- Dry Age-Related Macular Degeneration
- By Value
- Wet Age-Related Macular Degeneration
- By Value
- Introduction
- By Stage Of Disease
- Introduction
- Stage Of Disease By Value
- Early-Stage AMD
- By Value
- Intermediate AMD
- By Value
- Late-Stage AMD
- By Value
- Introduction
- By Route Of Administration
- Introduction
- Route Of Administration By Value
- Intravenous Route
- By Value
- Intravitreal Route
- By Value
- Introduction
- By Sales Channels
- Introduction
- Sales Channels By Value
- Ambulatory Surgical Centers
- By Value
- Hospitals
- By Value
- Other Sales Channels
- By Value
- Introduction
- China
- Korea
- Japan
- India
- Australia
- Taiwan
- South East Asia
- Rest Of Asia-Pacific
- Middle East And Africa Market Analysis
- Introduction
- By Type
- Introduction
- Type By Value
- Dry Age-Related Macular Degeneration
- By Value
- Wet Age-Related Macular Degeneration
- By Value
- Introduction
- By Stage Of Disease
- Introduction
- Stage Of Disease By Value
- Early-Stage AMD
- By Value
- Intermediate AMD
- By Value
- Late-Stage AMD
- By Value
- Introduction
- By Route Of Administration
- Introduction
- Route Of Administration By Value
- Intravenous Route
- By Value
- Intravitreal Route
- By Value
- Introduction
- By Sales Channels
- Introduction
- Sales Channels By Value
- Ambulatory Surgical Centers
- By Value
- Hospitals
- By Value
- Other Sales Channels
- By Value
- Introduction
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Egypt
- Nigeria
- Rest Of MEA
- LATAM Market Analysis
- Introduction
- By Type
- Introduction
- Type By Value
- Dry Age-Related Macular Degeneration
- By Value
- Wet Age-Related Macular Degeneration
- By Value
- Introduction
- By Stage Of Disease
- Introduction
- Stage Of Disease By Value
- Early-Stage AMD
- By Value
- Intermediate AMD
- By Value
- Late-Stage AMD
- By Value
- Introduction
- By Route Of Administration
- Introduction
- Route Of Administration By Value
- Intravenous Route
- By Value
- Intravitreal Route
- By Value
- Introduction
- By Sales Channels
- Introduction
- Sales Channels By Value
- Ambulatory Surgical Centers
- By Value
- Hospitals
- By Value
- Other Sales Channels
- By Value
- Introduction
- Brazil
- Mexico
- Argentina
- Chile
- Colombia
- Rest Of LATAM
- Competitive Assessment
- Adoption Matrix
- Macular Degeneration Treatment Market Share By Manufacturers
- Macular Degeneration Treatment Market Ranking By Revenue For Manufacturers
- Average Price By Manufacturers
- Vendor Footprint Analysis
- Market Players Assessment
- Novartis AG
- Overview
- Business Information
- Revenue
- ASP
- Gross Margin
- Swot Analysis
- Recent Developmments
- Pfizer Inc.
- Panoptica
- Bausch Health Companies Inc.
- Regeneron Pharmaceutical Inc.
- Aerie Pharmaceutical Inc.
- REGENXBIO Inc.
- Bayer AG.
- Novartis AG
- Research Methodology
- Research Data
- Secondary Data
- Major Secondary Sources
- Key Data From Secondary Sources
- Primary Data
- Key Data From Primary Sources
- Breakdown Of Primaries
- Secondary And Primary Research
- Key Industry Insights
- Secondary Data
- Market Size Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Projection
- Research Assumptions
- Assumptions
- Limitations
- Risk Assessment
- Research Data
- APPENDIX
- Discussion Guide
- Customization Options
- Related Reports
- DISCLAIMER
Table of Content and Figure @ https://straitsresearch.com/report/macular-degeneration-treatment-market/toc
Recent Development
- In August 2022, Novartis intends to completely spin off the Sandoz division to establish a standalone business.
- In September 2022, Bayer will present new cardiorenal results for Kerendia in individuals with early-stage chronic kidney disease and type 2 diabetes (finerenone).
News Media
Global Macular Degeneration Treatment Market Ascends at a Noteworthy CAGR of 7.06%
Global Lacrimal Devices Market to Grow at a CAGR of 3.5%
Posterior Segment Eye Disorders Market Share Extends at a Healthy CAGR of 4.83% by 2031
Have a Look at the Related Research Report
Eye Health Supplements Market: Information by Supplement Category (Antioxidants), Therapeutic Domain (Age-Related Macular Degeneration), Product Type, and Region — Forecast till 2029
Dry Eye Syndrome Treatment Market: Information by Product (Cyclosporine, Artificial Tears), Dosage Form (Liquid Drops, Gel), Disease Type (Evaporative, Aqueous Deficient), and Regions-Forecast Till 2031
Posterior Segment Eye Disorders Market: Information by Product (Drugs and Devices), Application (Macular Degeneration, Glaucoma, and Diabetic Retinopathy), and Regions—Forecast Till 2031
Eye Tracking Market: Information by Type (Optical, Eye Attached Tracking), Application (Healthcare, Consumer Electronics), Component (Hardware, Software), and Region — Forecast till 2030
Lacrimal Devices Market: Information by Product (Intubation Sets, Stents And Tubes, Dilators), Applications (Glaucoma, Dry Eye, Lacrimal Gland Inflammation), and Regions—Forecast Till 2031
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
Email: [email protected]
Follow Us: LinkedIn | Facebook | Instagram | Twitter
Artificial Intelligence
Tyne and Wear Fire and Rescue Service U.K. to Deploy Motorola Solutions’ Cloud-Hosted Control Room Solution
New response system helps streamlining workflows, strengthening resilience and improving safety for more than 1 million people in Northeast England
LONDON, Sept. 30, 2024 /PRNewswire/ — Tyne and Wear Fire and Rescue Service has announced that it is strengthening its emergency response capabilities through a cloud-hosted Control Room Solution (CRS) from Motorola Solutions (NYSE: MSI). This move will foster digitalisation, streamline workflows and offer the agency the ability to better scale operations in critical situations such as flooding and wildfires, which have increased in frequency in the U.K. in recent years.
“Our objective is to create one of the safest communities in the country,” said Phil Clark, Area Manager for mobilising and digital transformation at Tyne and Wear Fire and Rescue Service. “We are amongst the fastest responding fire and rescue services in the U.K. for dwelling fires with an average response time of 5 minutes 58 seconds.”
“We will continue to invest in new technologies and plan to offer other fire and rescue services the opportunity to join our newly created control room solution,” said Area Manager Clark. “In doing so, we’ll be able to seamlessly exchange information during joint operations, increase scalability to accommodate varying demand levels, and foster greater cooperation and faster responses in critical situations. Our relationship with Motorola Solutions will enable us to realise and deliver our operational vision, which will ultimately help to save lives and put Tyne and Wear Fire and Rescue Service at the forefront of Control Room technology in the U.K.”
Every day, more than 1 million people rely on Tyne and Wear Fire and Rescue Service, who operate 17 community fire stations in Northeast England. Their responsibilities across the community include responding to primary and secondary fires, road traffic collisions, civil emergencies, water and structural rescues and delivering fire safety advice to residents and businesses.
The browser-based CRS enables staff to access the control room by securely logging on from any location to set up mobile command posts or provide remote support for incidents. The new platform will integrate Motorola Solutions’ CommandCentral Evidence software for storing and securely handling control room voice recordings, unifying critical communications and data in one platform, while also linking to the appropriate cases.
“Demand on the fire and rescue service has evolved over the years, and emergency services continue to respond to a wide range of complex incidents,” said Fergus Mayne, U.K. and Ireland country manager at Motorola Solutions. “Our cloud-hosted CRS solution benefits Tyne and Wear Fire and Rescue Service with an intuitive and unified response system that integrates all communications into one efficient and resilient work environment.”
About Motorola Solutions
Motorola Solutions is solving for safer. We build and connect technologies to help protect people, property and places. Our solutions enable the collaboration between public safety agencies and enterprises that’s critical for a proactive approach to safety and security. Learn more about how we’re solving for safer communities, safer schools, safer hospitals, safer businesses – safer everywhere – at www.motorolasolutions.com.
Tyne and Wear Fire and Rescue Service
Tyne and Wear Fire and Rescue Service leads the operational delivery of fire and rescue, including public protection, emergency prevention and resilience for the five local authority areas of Gateshead, Newcastle, North Tyneside, South Tyneside and Sunderland.
The fire service operates from 17 community fire stations across Tyne and Wear, with our stations, employees and appliances strategically placed across the region to ensure efficient and effective response to fire and rescue emergencies. www.twfire.gov.uk
Photo – https://mma.prnewswire.com/media/2517802/TWFRS_Control_Room.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tyne-and-wear-fire-and-rescue-service-uk-to-deploy-motorola-solutions-cloud-hosted-control-room-solution-302261318.html
Artificial Intelligence
Heimdal and emt Distribution Aim to Dominate the Middle East Cybersecurity Market
COPENHAGEN, Denmark and DUBAI, UAE, Sept. 30, 2024 /PRNewswire/ — Heimdal and emt Distribution announce a strategic partnership that combines Heimdal’s advanced cybersecurity solutions with emt Distribution’s deep market expertise.
The collaboration will deliver sophisticated yet user friendly products to the Middle East. With Heimdal offering the widest cybersecurity stack in the world, and emt Distribution being the region’s leading distributor, the partnership is well-positioned for success.
Together, they are committed to educating the market on how strategic consolidation, training, and strong vendor relationships will maximize value.
Bringing a new dynamic to the market
Under this partnership, the two parties have promised to:
Roll out Heimdal’s Patch Management solution right away, as it’s a clear improvement over existing tools in the market.Provide local hosting in the United Arab Emirates by 2025, offering compliant, high-performance cloud services tailored to regional needs.Drive new technology adoption with pioneering tools, like the Threat Hunting and Action Center, along with emt Distribution’s market know-how.Offer easy-to-use technology, hands-on training, and show how a SOC can close security gaps while boosting profits.M Mobasseri, Co-Founder and CEO of emt Distribution META: “As we work closely with many cybersecurity experts and CISOs, we consistently encounter a range of challenges, particularly the complexity of managing numerous platforms. These platforms not only require specialized expertise but are also resource-intensive and costly.”
“Having known Heimdal for many years, I’ve witnessed their substantial investments in addressing these challenges and their development of a comprehensive cybersecurity platform that meets the critical needs of customers in the region.”
“Together with Heimdal, we are striving to integrate best-of-breed technologies into a unified platform, with plans for local hosting in 2025 to ensure compliance for businesses of all sizes. In addition, we are excited to announce special terms for our channel partners, aimed at maximizing their growth and profitability.”
Jesper Frederiksen, CEO of Heimdal, commented on the announcement: “Heimdal is pleased to announce a strategic partnership with emt Distribution, the leading security distributor in the Middle East. This collaboration comes in response to the rapidly growing demand for advanced cybersecurity solutions across the region.”
“By joining forces with emt Distribution, Heimdal aims to leverage their extensive network of resellers to provide cybersecurity solutions to organizations throughout the Middle East. Our joint initiative will focus on empowering organizations to significantly reduce their cyber risk exposure through Heimdal’s easy-to-use and cost-effective security solutions and emt Distribution’s unparalleled market reach.”, he added.
About emt Distribution META
emt Distribution META is a channel company with over 30 years of experience in security distribution, offering cyber threat mitigation solutions for Enterprises, SMBs, and MSPs. Committed to selling through channel partners, emt supports a large reseller base and provides technical support and professional services.
For more information, visit emt Distribution.
About Heimdal
Established in Copenhagen in 2014, Heimdal® empowers CISOs, security teams, and IT administrators to improve their security operations, reduce alert fatigue, and implement proactive measures through a unified command and control platform.
Heimdal’s award-winning cybersecurity solutions span the entire IT estate, addressing challenges from endpoint to network levels, including vulnerability management, privileged access, Zero Trust implementation, and ransomware prevention.
For more information, visit Heimdal.
For further press information:
Madalina PopoviciMedia Relations [email protected]
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/heimdal-security/r/heimdal-and-emt-distribution-aim-to-dominate-the-middle-east-cybersecurity-market,c4044480
The following files are available for download:
https://mb.cision.com/Main/22623/4044480/3028629.pdf
Heimdal and emt Distribution Partnership – Press Release
https://news.cision.com/heimdal-security/i/heimdal-and-emt-distribution-partnership,c3338145
Heimdal and emt Distribution Partnership
View original content:https://www.prnewswire.co.uk/news-releases/heimdal-and-emt-distribution-aim-to-dominate-the-middle-east-cybersecurity-market-302262358.html
Artificial Intelligence
MSD in Strategic collaboration with Briya for Innovative RWE data analysis projects
TEL AVIV, Israel, Sept. 30, 2024 /PRNewswire/ — MSD, a leading multinational pharmaceutical company successfully completes a first-of-its-kind strategic collaboration with Briya, a medical data retrieval network. This groundbreaking partnership enabled innovative data analysis projects on three critical disease areas MSD plays a part in. Leveraging Briya’s advanced data platform, the partnership facilitated comprehensive data access for these important data analysis projects.
By utilizing Briya’s cutting-edge technology, MSD was able to access, standardize, and analyze real-world and accurate data from diverse sources in real time. This enabled the project to provide a more accurate and holistic view of the patient journey.
“We are happy to have partnered with Briya on this important initiative.” said Udi Cohen, MSD Israel Commercial Operations Director. “Briya’s data curation techniques shed new light on analyzing clinical data, including free text and medical notes, to generate insights about patients. I believe this will allow meaningful clinical insights to be obtained in the future.”
Briya’s platform ensured that all data was handled with the highest standards of security and privacy, complying with regulatory requirements and safeguarding patient information. This collaboration not only exemplifies the power of data in driving medical research but also underscores the importance of strategic partnerships in addressing healthcare challenges.
“Our collaboration with MSD marks a significant milestone in our mission to support innovative research through our robust data solutions,” said David Lazerson, CEO and Co-founder of Briya. “We are proud to have enabled this RWE project and look forward to continuing to work together to improve patient care and outcomes.”
This collaboration demonstrates that combining advanced data capabilities with pharmaceutical expertise can drive impactful healthcare outcomes. MSD and Briya are committed to ongoing innovation and partnership to further the advancement of medical science and improve patient lives.
About MSD:
MSD is a global healthcare leader working to help the world be well. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world. For more information, visit https://www.msd.com/.
About Briya:
Briya’s global healthcare data network taps into the potential of patient-level data, fostering seamless collaboration between hospitals, clinics, health systems, researchers, and life sciences organizations worldwide while upholding regulations. Through this comprehensive solution, data sharing is securely facilitated in real-time, enabling standardization and harmonization of longitudinal data from diverse sources and systems with extreme ease. By leveraging Briya’s expansive network, organizations establish themselves as pioneers in research and innovation, enhance visibility within their sectors, and open up new avenues for revenue generation visit www.briya.com.
Contact Details:Mor Pecht [email protected]
Photo – https://mma.prnewswire.com/media/2518699/MSD_and_Briya.jpg
View original content:https://www.prnewswire.co.uk/news-releases/msd-in-strategic-collaboration-with-briya-for-innovative-rwe-data-analysis-projects-302262246.html
-
Artificial Intelligence3 days agoCluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review
-
Uncategorized3 days agoMC Digital Realty wins Frost & Sullivan’s 2024 Japan Data Center Services Company of the Year Award
-
Artificial Intelligence7 days agoEC-Council Unleashes AI-Powered Ethical Hackers on Cybercrime
-
Artificial Intelligence7 days agoHappiest Minds’ MD & CFO, Venkatraman Narayanan, recognized as the Leading CFO of the Year at the CII CFO Excellence Awards 2023-24
-
Artificial Intelligence7 days agoIBM and NASA Release Open-Source AI Model on Hugging Face for Weather and Climate Applications
-
Artificial Intelligence7 days agoSSCL partners with PolyAI to empower next-generation customer experience
-
Artificial Intelligence7 days agoBITBOT1000 Revolutionizes the Digital Market Landscape with AI-Driven Solutions
-
Artificial Intelligence6 days agoHuawei and Partners Jointly Release Intelligent Distribution Solution to Amplify Electric Power Intelligence
